Evidence map›Paper›PMID 26015967›Full record

ArticleMolecular therapy. Methods & clinical development2014

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.

Ryan Burnett, Carlos E Ibañez, Pär L Pettersson, Ching-I Chen, Shraddha Parab, Tiffany Huang, Joan Robbins, Krystof Bankiewicz, Manish Aghi, Christopher Logg and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ryan BurnettTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Carlos E IbañezTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Pär L PetterssonTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Ching-I ChenTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Shraddha ParabTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Tiffany HuangTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Joan RobbinsTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Krystof BankiewiczDepartment of Neurological Surgery, University of California San Francisco (UCSF) , San Francisco, CA, USA.
Manish AghiDepartment of Neurological Surgery, University of California San Francisco (UCSF) , San Francisco, CA, USA.
Christopher LoggDepartment of Medicine, University of California Los Angeles (UCLA) , Los Angeles, CA, USA.
Noriyuki KasaharaDepartment of Medicine, University of California Los Angeles (UCLA) , Los Angeles, CA, USA.
Dan PertschukTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Harry E GruberTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
Douglas J JollyTocagen Inc., Bunker Hill St. , San Diego, CA, USA.
University of California, San Francisco · US

Funding

Translational Development of Replication-Competent Retrovirus VectorsU01NS059821 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KASAHARA, NORIYUKI · 2010 to 2013
$2.9M
NINDS NIH HHS U01 NS059821
6 · The paper itself

Abstract

Toca 511 is a novel retroviral replicating vector, encoding a modified yeast cytosine deaminase, administered to recurrent high grade glioma patients in Phase 1 trials by stereotactic, transcranial injection into the tumor or into the walls of the resection cavity. A key issue, with little published data, is vector biocompatibility with agents likely to be encountered in a neurosurgical setting. We tested biocompatibility of Toca 511 with: delivery devices; MRI contrast agents, including ProHance supporting coinjection for real time MRI-guided intratumoral delivery; hemostatic agents; biofluids (blood and cerebrospinal fluid); potential adjuvants; and a needleless vial adapter that reduces risk of accidental needle sticks. Toca 511 is stable upon thawing at ambient temperature for at least 6 hours, allowing sufficient time for administration, and its viability is not reduced in the presence of: stainless steel and silica-based delivery devices; the potential MRI contrast agent, Feraheme; ProHance at several concentrations; the hemostatic agent SURGIFOAM; blood; cerebrospinal fluid; and the needleless vial adapter. Toca 511 is not compatible with the hemostatic agent SURGICEL or with extended exposures to titanium-based biopsy needles.

Identifiers

PMID26015967
PMCPMC4362351
OpenAlexW2097228295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.